Validation of surrogate end points in multiple randomized clinical trials with failure time end points
Helena Geys and
Journal of the Royal Statistical Society Series C, 2001, vol. 50, issue 4, 405-422
Before a surrogate end point can replace a final (true) end point in the evaluation of an experimental treatment, it must be formally ‘validated’. The validation will typically require large numbers of observations. It is therefore useful to consider situations in which data are available from several randomized experiments. For two normally distributed end points Buyse and co‐workers suggested a new definition of validity in terms of the quality of both trial level and individual level associations between the surrogate and true end points. This paper extends this approach to the important case of two failure time end points, using bivariate survival modelling. The method is illustrated by using two actual sets of data from cancer clinical trials.
References: Add references at CitEc
Citations: View citations in EconPapers (13) Track citations by RSS feed
Downloads: (external link)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:bla:jorssc:v:50:y:2001:i:4:p:405-422
Ordering information: This journal article can be ordered from
http://ordering.onli ... 1111/(ISSN)1467-9876
Access Statistics for this article
Journal of the Royal Statistical Society Series C is currently edited by R. Chandler and P. W. F. Smith
More articles in Journal of the Royal Statistical Society Series C from Royal Statistical Society Contact information at EDIRC.
Bibliographic data for series maintained by Wiley Content Delivery ().